| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Amer Budayr, Thida C Tan, Joan C Lo, Jonathan G Zaroff, Grace H Tabada, Jingrong Yang, Alan S G. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study. BMC endocrine disorders. vol 20. issue 1. 2020-11-23. PMID:32075620. |
we examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists. |
2020-11-23 |
2023-08-13 |
Not clear |
| Sunita M C De Sousa, John Baranoff, R Louise Rushworth, Jessica Butler, Jane Sorbello, Juanita Vorster, Tanya Thompson, Ann I McCormack, Warrick J Inder, David J Torp. Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors. The Journal of clinical endocrinology and metabolism. vol 105. issue 3. 2020-11-09. PMID:31580439. |
impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. |
2020-11-09 |
2023-08-13 |
Not clear |
| Atefeh Bamarinejad, Shidrokh Nasiri, Fatemeh Bamarinejad, Rezvan Salehidoost, Elahe Zare-Farashband. Schizophrenia and Macroprolactinoma: Is There a Deep Link? Advanced biomedical research. vol 9. 2020-10-22. PMID:33072650. |
iatrogenic hyperprolactinemia is a well-known side effect of dopamine antagonist drugs for treatment in a patient with schizophrenia. |
2020-10-22 |
2023-08-13 |
Not clear |
| Junjing Su, Ulf Simonsen, Jørn Carlsen, Soren Mellemkjae. Pulmonary Artery Occlusion and Mediastinal Fibrosis in a Patient on Dopamine Agonist Treatment for Hyperprolactinemia. Frontiers in pharmacology. vol 8. 2020-10-01. PMID:28775691. |
pulmonary artery occlusion and mediastinal fibrosis in a patient on dopamine agonist treatment for hyperprolactinemia. |
2020-10-01 |
2023-08-13 |
Not clear |
| Eva Philipse, Ester Philipse, Theodorus Twickler, Amaryllis Van Craenenbroeck, Marie Madeleine Couttenye, Luc Van Gaa. An Intact Dopamine Sensitivity in the Brain: A Necessity to Recover Hyperprolactinemia and Galactorrhea in a Female Hemodialysis Patient? Case reports in nephrology. vol 2017. 2020-10-01. PMID:28791188. |
an intact dopamine sensitivity in the brain: a necessity to recover hyperprolactinemia and galactorrhea in a female hemodialysis patient? |
2020-10-01 |
2023-08-13 |
Not clear |
| Alpesh Goyal, Mohd Ashraf Gani. Idiopathic Hyperprolactinemia Presenting as Polycystic Ovary Syndrome in Identical Twin Sisters: A Case Report and Literature Review. Cureus. vol 10. issue 7. 2020-10-01. PMID:30250766. |
considering the fact that androgen excess could be caused by either insulin resistance or hyperprolactinemia, we decided to treat one sister with insulin sensitizer metformin and other with dopamine agonist cabergoline. |
2020-10-01 |
2023-08-13 |
Not clear |
| Alpesh Goyal, Mohd Ashraf Gani. Idiopathic Hyperprolactinemia Presenting as Polycystic Ovary Syndrome in Identical Twin Sisters: A Case Report and Literature Review. Cureus. vol 10. issue 7. 2020-10-01. PMID:30250766. |
although rare, hyperprolactinemia can lead to androgen excess by increasing adrenal androgen secretion, which improves with dopamine agonist therapy. |
2020-10-01 |
2023-08-13 |
Not clear |
| Gulen Guler, Meryem Ozlem Kutuk, Halil Kar. Amenorrhea as a Side Effect of Low Dose Aripiprazole: An Adolescent Case. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 16. issue 3. 2020-09-30. PMID:30121986. |
hyperprolactinemia is one of major side effects of treatment with antipsychotics, but aripiprazole is known as a dopamine stabilizer antipsychotic which can be used to improve hyperprolactinemia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Kwabena Nkansah-Amankra, Sathyanarayan Sudhantha. Medication-induced obstructive uropathy and hyperprolactinemia in a pediatric patient. Clinical case reports. vol 7. issue 10. 2020-09-30. PMID:31624611. |
hyperprolactinemia can result from a pituitary tumor or decreased dopamine levels due to compression of the pituitary stalk. |
2020-09-30 |
2023-08-13 |
Not clear |
| Satyakam Mohapatra, Mihir Ranjan Naya. Cabergoline-induced Mania in a Patient of Pituitary Microadenoma. Indian journal of psychological medicine. vol 39. issue 3. 2020-09-28. PMID:28615773. |
cabergoline, a dopamine agonist agent, is commonly used in the treatment of hyperprolactinemia, parkinson's disease, restless leg syndrome, and antipsychotic-induced prolactin elevation. |
2020-09-28 |
2023-08-13 |
Not clear |
| Andrea Glezer, Marcello D Bronstei. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary. vol 23. issue 1. 2020-09-28. PMID:31792668. |
the gold-standard treatment is dopamine agonist (da) which can reverse hyperprolactinemia and hypogonadism, and promote tumor shrinkage in the majority of cases. |
2020-09-28 |
2023-08-13 |
Not clear |
| Mark E Molitc. Dopamine agonists and antipsychotics. European journal of endocrinology. vol 183. issue 3. 2020-08-05. PMID:32508315. |
the psychiatric benefits of antipsychotic agents involve blocking the d2 and other dopamine receptors but this blockade often also causes hyperprolactinemia. |
2020-08-05 |
2023-08-13 |
Not clear |
| Tim J Fyfe, Barrie Kellam, David A Sykes, Ben Capuano, Peter J Scammells, J Robert Lane, Steven J Charlton, Shailesh N Mistr. Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D Journal of medicinal chemistry. vol 62. issue 21. 2020-06-15. PMID:31580666. |
structure-kinetic profiling of haloperidol analogues at the human dopamine d haloperidol is a typical antipsychotic drug (apd) associated with an increased risk of extrapyramidal side effects (epss) and hyperprolactinemia relative to atypical apds such as clozapine. |
2020-06-15 |
2023-08-13 |
human |
| Chao Tang, Ruixin Sun, Guodao Wen, Chunyu Zhong, Jin Yang, Junhao Zhu, Zixiang Cong, Xiaoying Luo, Chiyuan M. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively. Cell death & disease. vol 10. issue 5. 2020-05-19. PMID:31000722. |
the treatment of hyperprolactinemia is based on the use of dopamine agonists, mainly bromocriptine (brc) and cabergoline (cab). |
2020-05-19 |
2023-08-13 |
Not clear |
| Sandra Pekić, Milica Medic Stojanoska, Vera Popovi. Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management. Neuroendocrinology. vol 109. issue 1. 2020-05-06. PMID:30347396. |
the current strategy for microprolactinomas is not to treat hyperprolactinemia in menopause if it recurrs after discontinuation of dopamine agonists. |
2020-05-06 |
2023-08-13 |
Not clear |
| Sandra Pekić, Milica Medic Stojanoska, Vera Popovi. Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management. Neuroendocrinology. vol 109. issue 1. 2020-05-06. PMID:30347396. |
for a change in strategy, i.e., for the potential benefits from treatment of hyperprolactinemia in the postmenopausal period with dopamine agonists concerning weight loss, improved insulin sensitivity, decreased fracture risk, and improved sexuality, more evidence is needed. |
2020-05-06 |
2023-08-13 |
Not clear |
| Sarah N Framnes-DeBoer, Ellen Bakke, Suma Yalamanchili, Hannah Peterson, Darleen A Sandoval, Randy J Seeley, Deanna M Arbl. Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor. American journal of physiology. Endocrinology and metabolism. vol 318. issue 1. 2020-05-05. PMID:31794265. |
bromocriptine, a dopamine d2 receptor agonist originally used for the treatment of hyperprolactinemia, is largely successful in reducing hyperglycemia and improving glucose tolerance in type 2 diabetics. |
2020-05-05 |
2023-08-13 |
Not clear |
| Diana Z Osmanova, Maxim B Freidin, Olga Yu Fedorenko, Ivan V Pozhidaev, Anastasiia S Boiko, Natalia M Vyalova, Vladimir V Tiguntsev, Elena G Kornetova, Anton J M Loonen, Arkadiy V Semke, Bob Wilffert, Nikolay A Bokhan, Svetlana A Ivanov. A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia. BMC medical genetics. vol 20. issue Suppl 1. 2020-04-02. PMID:30967134. |
hyperprolactinemia (hprl) is a classical side effect of antipsychotic drugs primarily attributed to blockade of dopamine d2 receptors (drd2s) on the membranes of lactotroph cells within the pituitary gland. |
2020-04-02 |
2023-08-13 |
Not clear |
| Martine Claude Etoa Etoga, Eugène Sobngwi, Pelagie Ngoune, Emmanuella Doh, Francine Mendane Mekobe, Noel Mbango-Ekouta, Mesmin Dehayem, Pascal Foumane, Jean Claude Mbany. Clinical profile and early therapeutic response to cabergoline of patients with hyperprolactinemia in a Cameroonian population. The Pan African medical journal. vol 35. 2020-03-10. PMID:32117518. |
dopamine agonists are the gold standard treatment of hyperprolactinemia. |
2020-03-10 |
2023-08-13 |
Not clear |
| N Tani, T Ikeda, Y Aoki, A Shida, S Oritani, T Ishikaw. Evaluation of screening for drug use using postmortem prolactin levels in serum and cerebrospinal fluid. Human & experimental toxicology. vol 38. issue 11. 2020-01-30. PMID:31319705. |
however, the use of dopamine (da) antagonists may lead to hyperprolactinemia under certain clinical conditions. |
2020-01-30 |
2023-08-13 |
Not clear |